Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats.
The pathophysiologic basis of tardive dyskinesia remains unclear, but several lines of evidence suggest that persistent neuronal changes in the basal ganglia produced by oxidative stress or glutamate toxicity may play a role, especially in the elderly. In the present study we examined whether histopathological alterations in substantia nigra are related to oral dyskinesia in a rodent model of tardive dyskinesia. Haloperidol decanoate (38 mg/kg/4 weeks) was administered to young (8 weeks) and old (38 weeks) rats for a total period of 28 weeks, and the development of vacuous chewing movements (VCM) was observed. Rats with high and low levels of VCM and saline-treated controls were analyzed for histopathological alterations. Reduced nerve cell number and atrophic neurons were prominent features in the substantia nigra of old rats with high levels of VCM. Some alterations were also present in the substantia nigra of the old rats with low levels of VCM and young rats with high VCM levels, but these were significantly less affected than the high VCM rats. These results show that the development of haloperidol-induced oral dyskinesias in old rats is associated with histopathological alterations in the substantia nigra. This suggests that nigral degeneration induced by neuroleptics may contribute to the development of persistent VCM in rats and possibly irreversible tardive dyskinesia in humans.
Andreassen
O A
OA
The Research Section, Department of Psychiatry, Ullevaal University Hospital and University of Oslo, Kirkeveien 166, N-0407, Oslo, Norway
Ferrante
R J
RJ
Aamo
T O
TO
Beal
M F
MF
Jørgensen
H A
HA
D000375:Aging; D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002452:Cell Count; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000473:pathology*; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity*; D008409:Mastication / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013239:Stereotyped Behavior / Q000145:classification / Q000187:drug effects; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology*; D013995:Time; D013997:Time Factors
C033563:haloperidol decanoate; D006220:Haloperidol